Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TXA in Anticoagulated TSA Patients
NCT04560010Phase 4Terminated
- Sponsor
- NYU Langone Health
- Start
- Oct 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of tranexamic acid (2 arms), sponsored by NYU Langone Health. Primary endpoints: Calculated Total Blood Loss and Total Surgical Drain Output. Started Oct 2020; status: terminated.
02
Drugs
tranexamic acid
Beyond the preview
Go deeper on NCT04560010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560010.